
|Articles|March 15, 2020
Monograph Development: Why and When to Participate
Author(s)J. Mark Wiggins, Joseph A. Albanese
This article explores another proactive advocacy approach that a bio/pharmaceutical company may take through participation in the development of new and revised monographs in the various pharmacopoeias.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
5